(Q39903042)

15 September 2017

title

Update on the clinical pharmacogenomics of organ transplantation (English)

1 reference

15 September 2017

main subject

organ transplantation

1 reference

1 reference

Gilbert J Burckart

1

1 reference

15 September 2017

Shashi Amur

series ordinal

2

1 reference

15 September 2017

publication date

1 February 2010

1 reference

15 September 2017

1 reference

15 September 2017

volume

11

1 reference

15 September 2017

issue

2

1 reference

15 September 2017

page(s)

227-236

1 reference

Pharmacogenomics: the key to improved drug therapy in transplant patients

15 September 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.177

Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.177

Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.177

CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.177

Influence of CYP3A5 gene polymorphisms of donor rather than recipient to tacrolimus individual dose requirement in liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.177

The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.177

No association between single nucleotide polymorphisms and the development of nephrotoxicity after orthotopic heart transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.177

Effect of CYP3A5 genotype on renal allograft recipients treated with tacrolimus.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.177

Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.177

CYP3A5 and ABCB1 genes and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.177

CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.177

Reduced methylprednisolone clearance causing prolonged pharmacodynamics in a healthy subject was not associated with CYP3A5*3 allele or a change in diet composition

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.177

Influence of CYP3A5, ABCB1 and NR1I2 polymorphisms on prednisolone pharmacokinetics in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.177

PXR: a xenobiotic receptor of diverse function implicated in pharmacogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.177

CYP3A5 genotype is associated with longer patient survival after kidney transplantation and long-term treatment with cyclosporine.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.177

A "silent" polymorphism in the MDR1 gene changes substrate specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.177

The impact of pharmacogenomic factors on steroid dependency in pediatric heart transplant patients using logistic regression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.177

The impact of P-glycoprotein and Mrp2 on mycophenolic acid levels in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.177

Impact of ABCB1 (MDR1) haplotypes on tacrolimus dosing in adult lung transplant patients who are CYP3A5 *3/*3 non-expressors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.177

Influence of ABCB1 genetic polymorphisms on cyclosporine intracellular concentration in transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.177

ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.177

Influence of ABCB1 polymorphisms and haplotypes on tacrolimus nephrotoxicity and dosage requirements in children with liver transplant.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.177

Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.177

ABCB1 C3435T and G2677T/A polymorphism decreased the risk for steroid-induced osteonecrosis of the femoral head after kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.177

Role of MDR1 gene polymorphisms in gingival overgrowth induced by cyclosporine in transplant patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.177

The impact of pharmacogenomic factors on acute persistent rejection in adult lung transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.177

Haplotypic structure of ABCB1/MDR1 gene modifies the risk of the acute allograft rejection in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.177

Association of four DNA polymorphisms with acute rejection after kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.177

ABCB1 genotypes predict cyclosporine-related adverse events and kidney allograft outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.177

The rationale for and limitations of therapeutic drug monitoring for mycophenolate mofetil in transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.177

New insights into the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: possible consequences for therapeutic drug monitoring in solid organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.177

Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.177

UGT1A9 -275T>A/-2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.177

Expression of IMPDH1 and IMPDH2 after transplantation and initiation of immunosuppression.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.177

IMPDH1 gene polymorphisms and association with acute rejection in renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.177

Mutations in the inosine monophosphate dehydrogenase 1 gene (IMPDH1) cause the RP10 form of autosomal dominant retinitis pigmentosa

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.177

Interpatient variability in IMPDH activity in MMF-treated renal transplant patients is correlated with IMPDH type II 3757T > C polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.177

A novel variant L263F in human inosine 5'-monophosphate dehydrogenase 2 is associated with diminished enzyme activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.177

Microarrays: a monitoring tool for transplant patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.177

Molecular and immunohistochemical characterization of the onset and resolution of human renal allograft ischemia-reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.177

Gene expression and biomarkers in renal transplant ischemia reperfusion injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.177

Novel insights into lung transplant rejection by microarray analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.177

Designer genes: Filling the gap in transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.177

Applying genomics to organ transplantation medicine in both discovery and validation of biomarkers.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.177

Immunosuppressive drug-free operational immune tolerance in human kidney transplant recipients: Part I. Blood gene expression statistical analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.177

Chipping into the human genome: novel insights for transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.177

Converting a breast cancer microarray signature into a high-throughput diagnostic test.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.177

Clinical utilities of peripheral blood gene expression profiling in the management of cardiac transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.177

Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.177

Transcriptional signals of T-cell and corticosteroid-sensitive genes are associated with future acute cellular rejection in cardiac allografts

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.177

Blood pressure as an example of a biomarker that functions as a surrogate

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.177

Qualification of biomarkers for drug development in organ transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.177

The proteogenomic path towards biomarker discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.177

Using gene arrays in diagnosis of rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.177

Clinical implications and longitudinal alteration of peripheral blood transcriptional signals indicative of future cardiac allograft rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.177

Biomarker qualification pilot process at the US Food and Drug Administration

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.177

Genetic prediction of renal transplant outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.177

Pharmacogenetics in transplant patients: can it predict pharmacokinetics and pharmacodynamics?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.177

Understanding the genetic basis for adverse drug effects: the calcineurin inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.177

21 January 2018

Identifiers

DOI

10.2217/PGS.09.177

1 reference

15 September 2017

1 reference